Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice
Up to two-thirds of patients affected by spinal cord injury (SCI) develop central neuropathic pain (CNP), which has a high impact on their quality of life. Most of the patients are largely refractory to current treatments, and new pharmacological strategies are needed. Recently, it has been shown th...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00222/full |
| _version_ | 1811232734606000128 |
|---|---|
| author | Sílvia Castany Xavier Codony Daniel Zamanillo Manuel Merlos Enrique Verdú Pere Boadas-Vaello |
| author_facet | Sílvia Castany Xavier Codony Daniel Zamanillo Manuel Merlos Enrique Verdú Pere Boadas-Vaello |
| author_sort | Sílvia Castany |
| collection | DOAJ |
| description | Up to two-thirds of patients affected by spinal cord injury (SCI) develop central neuropathic pain (CNP), which has a high impact on their quality of life. Most of the patients are largely refractory to current treatments, and new pharmacological strategies are needed. Recently, it has been shown that the acute administration of the σ1R antagonist MR309 (previously developed as E-52862) at 28 days after spinal cord contusion results in a dose-dependent suppression of both mechanical allodynia and thermal hyperalgesia in wild-type CD-1 Swiss female mice. The present work was addressed to determine whether MR309 might exert preventive effects on CNP development by repeated administration during the first week after SCI in mice. To this end, the MR309 (16 or 32 mg/kg i.p.) modulation on both thermal hyperalgesia and mechanical allodynia development were evaluated weekly up to 28 days post-injury. In addition, changes in pro-inflammatory cytokine (TNF-α, IL-1β) expression and both the expression and activation (phosphorylation) of the N-methyl-D-aspartate receptor subunit 2B (NR2B-NMDA) and extracellular signal-regulated kinases (ERK1/2) were analyzed. The repeated treatment of SCI-mice with MR309 resulted in significant pain behavior attenuation beyond the end of the administration period, accompanied by reduced expression of central sensitization-related mechanistic correlates, including extracellular mediators (TNF-α and IL-1β), membrane receptors/channels (NR2B-NMDA) and intracellular signaling cascades (ERK/pERK). These findings suggest that repeated MR309 treatment after SCI may be a suitable pharmacologic strategy to modulate SCI-induced CNP development. |
| first_indexed | 2024-04-12T11:07:54Z |
| format | Article |
| id | doaj.art-7b1030e905f54d0da8b1d3084e69b5a1 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T11:07:54Z |
| publishDate | 2019-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-7b1030e905f54d0da8b1d3084e69b5a12022-12-22T03:35:41ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-03-011010.3389/fphar.2019.00222433451Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in MiceSílvia Castany0Xavier Codony1Daniel Zamanillo2Manuel Merlos3Enrique Verdú4Pere Boadas-Vaello5Research Group of Clinical Anatomy, Embryology and Neuroscience (NEOMA), Department of Medical Sciences, Universitat de Girona, Girona, SpainEsteve Pharmaceuticals, Drug Discovery and Preclinical Development, Parc Científic de Barcelona, Barcelona, SpainEsteve Pharmaceuticals, Drug Discovery and Preclinical Development, Parc Científic de Barcelona, Barcelona, SpainEsteve Pharmaceuticals, Drug Discovery and Preclinical Development, Parc Científic de Barcelona, Barcelona, SpainResearch Group of Clinical Anatomy, Embryology and Neuroscience (NEOMA), Department of Medical Sciences, Universitat de Girona, Girona, SpainResearch Group of Clinical Anatomy, Embryology and Neuroscience (NEOMA), Department of Medical Sciences, Universitat de Girona, Girona, SpainUp to two-thirds of patients affected by spinal cord injury (SCI) develop central neuropathic pain (CNP), which has a high impact on their quality of life. Most of the patients are largely refractory to current treatments, and new pharmacological strategies are needed. Recently, it has been shown that the acute administration of the σ1R antagonist MR309 (previously developed as E-52862) at 28 days after spinal cord contusion results in a dose-dependent suppression of both mechanical allodynia and thermal hyperalgesia in wild-type CD-1 Swiss female mice. The present work was addressed to determine whether MR309 might exert preventive effects on CNP development by repeated administration during the first week after SCI in mice. To this end, the MR309 (16 or 32 mg/kg i.p.) modulation on both thermal hyperalgesia and mechanical allodynia development were evaluated weekly up to 28 days post-injury. In addition, changes in pro-inflammatory cytokine (TNF-α, IL-1β) expression and both the expression and activation (phosphorylation) of the N-methyl-D-aspartate receptor subunit 2B (NR2B-NMDA) and extracellular signal-regulated kinases (ERK1/2) were analyzed. The repeated treatment of SCI-mice with MR309 resulted in significant pain behavior attenuation beyond the end of the administration period, accompanied by reduced expression of central sensitization-related mechanistic correlates, including extracellular mediators (TNF-α and IL-1β), membrane receptors/channels (NR2B-NMDA) and intracellular signaling cascades (ERK/pERK). These findings suggest that repeated MR309 treatment after SCI may be a suitable pharmacologic strategy to modulate SCI-induced CNP development.https://www.frontiersin.org/article/10.3389/fphar.2019.00222/fullspinal cord injurycentral neuropathic painMR309central sensitization-related biomarkerspro-inflammatory cytokines |
| spellingShingle | Sílvia Castany Xavier Codony Daniel Zamanillo Manuel Merlos Enrique Verdú Pere Boadas-Vaello Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice Frontiers in Pharmacology spinal cord injury central neuropathic pain MR309 central sensitization-related biomarkers pro-inflammatory cytokines |
| title | Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice |
| title_full | Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice |
| title_fullStr | Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice |
| title_full_unstemmed | Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice |
| title_short | Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice |
| title_sort | repeated sigma 1 receptor antagonist mr309 administration modulates central neuropathic pain development after spinal cord injury in mice |
| topic | spinal cord injury central neuropathic pain MR309 central sensitization-related biomarkers pro-inflammatory cytokines |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.00222/full |
| work_keys_str_mv | AT silviacastany repeatedsigma1receptorantagonistmr309administrationmodulatescentralneuropathicpaindevelopmentafterspinalcordinjuryinmice AT xaviercodony repeatedsigma1receptorantagonistmr309administrationmodulatescentralneuropathicpaindevelopmentafterspinalcordinjuryinmice AT danielzamanillo repeatedsigma1receptorantagonistmr309administrationmodulatescentralneuropathicpaindevelopmentafterspinalcordinjuryinmice AT manuelmerlos repeatedsigma1receptorantagonistmr309administrationmodulatescentralneuropathicpaindevelopmentafterspinalcordinjuryinmice AT enriqueverdu repeatedsigma1receptorantagonistmr309administrationmodulatescentralneuropathicpaindevelopmentafterspinalcordinjuryinmice AT pereboadasvaello repeatedsigma1receptorantagonistmr309administrationmodulatescentralneuropathicpaindevelopmentafterspinalcordinjuryinmice |